Hans Schweisfurth - Academia.edu (original) (raw)
Uploads
Papers by Hans Schweisfurth
Sarcoidosis is a multisystemic disorder of unknown origin which is characterized by noncaseating ... more Sarcoidosis is a multisystemic disorder of unknown origin which is characterized by noncaseating epithelioid cell granulomas with giant cells mainly in the lung. The average incidence is worldwide 16 (male) and 19 (female) per 100,000 inhabitants. In some studies it was described that patients with sarcoidosis have a higher risk of malignancies, especially of lung cancer. The results differ in the available studies. The role of smoking can probably be neglected as far as the development of lung cancer is concerned, because the patients with sarcoidosis are mainly non smokers. Regarding all of the published clinical studies with totally 22,439 patients with sarcoidosis, a coexistence of sarcoidosis and lung cancer was detected only in 198 (0.9 %) patients. According to the published case reports, mostly squamous lung cell carcinoma was histologically found, followed by adenocarcinoma. These results indicate that the coexistence of sarcoidosis and lung cancer is very rare.
DMW - Deutsche Medizinische Wochenschrift, 2008
Journal of Thoracic Oncology, 2007
standard treatment for this age group. Several recent studies suggest superiority of combination ... more standard treatment for this age group. Several recent studies suggest superiority of combination CT, but little is known about QoL during CT. Also better assessments are needed to select elderly pts suitable for combination CT. The aim of this study was to investigate the effect of both platinum-based regimens on changes in QoL and the tolerability of these treatments in elderly NSCLC pts. Methods: Eligible were pts ≥ 70 years with advanced NSCLC. They received carboplatin (AUC 5 day 1)-gemcitabine (1250 mg/m 2 days 1 and 8) or carboplatin (AUC 5 day 1)-paclitaxel (175 mg/m 2 day 1), q 3 weeks, for a maximum of 4 cycles. Darbepoetin was started if Hb < 11 g/dL. Primary endpoint was the change in global QoL from baseline compared with week 18, using the EORTC QLQ-C30. Among the secondary endpoints were toxicity, response rate and survival. In addition, the value of a comprehensive geriatric assessment (CGA) was used. Results: 182 pts were randomized. At the time of this analysis information was available on 168 pts. Mean age was 75 yrs (range 70-85). PS = 0 in 30%, 1 in 57% and 2 in 13%. 64% of pts completed all 4 cycles, 10% stopped treatment prematurely due to toxicity, 13% due to PD. Toxicity related dose-reductions occurred in 28 and 8% of pts and dose-delays in 15 and 3% of pts in the CG and CP arm, respectively. Overall, grade III/IV toxicity occurred in 65% of pts (75% in CG arm, 56% in CP arm), toxicity related SAEs in 17% (20% in CG arm, 15% in CP arm), and 36% experienced ≥ grade 2 neurological toxicity (30% CG arm, 43% CP arm). Response rates were 28% in the CG arm vs 20% in the CP arm. Median survival and progression-free survival were 7.7 and 4.7 months for the CG arm and 6.6 and 4.4 months for the CP arm, respectively. 56 % of pts in the CG arm and 49% in the CP arm completed both the QoL questionnaires at baseline and after 18 weeks. Mean global QoL score at baseline did not differ between both arms (66% for GC and CP). After 18 weeks the mean QoL score for the CG arm had decreased by 2% and for the CP arm by 8% (NS). Furthermore, changes in Qol scores over the period of 18 weeks did not differ significantly between both treatment arms. For experiencing grade III/IV toxicity related SAEs, neurological toxicities and for finishing all cycles, the use of a CGA was of predictive value. Conclusions: In elderly patients with advanced NSCLC differences in treatment-related toxicity from gemcitabine and paclitaxel administered with carboplatin have no differential influence on QoL. Response and survival rates are similar for both groups.
Atemwegs- und Lungenkrankheiten, 2006
Atemwegs- und Lungenkrankheiten, 2005
Atemwegs- und Lungenkrankheiten, 2010
Atemwegs- und Lungenkrankheiten, 2010
Sarcoidosis is a multisystem inflammatory disease of unidentified aetiology, which manifests as n... more Sarcoidosis is a multisystem inflammatory disease of unidentified aetiology, which manifests as noncaseating granulomas. It is hypothesised that sarcoidosis has an antigenic or inflammatory trigger that initiates the immune reaction in a susceptible host. Research is focusing on the correlation between sarcoidosis and exposure to airborne antigens, such as tree pollen, insecticides, mouldy environments, and inorganic particles. There are indications, that microbial cell wall agents, particularly agents from fungi, even in the absence of clinical infections can cause a late hypersensitivity reaction leading to granulomas. The occurrence of bacterial or fungal infections in sarcoidosis was repeatedly described and DNA or proteins of microbial organisms have been found. Cladosporium species were significantly enriched in specimen of patients with sarcoidosis. It is presumed that different inhaled microbial exposures, including moisture damage, can increase the risk of sarcoidosis, a ca...
Deutsche medizinische Wochenschrift, 2002
Sarcoidosis is a multisystemic disorder of unknown origin, which is characterized by non-caseatin... more Sarcoidosis is a multisystemic disorder of unknown origin, which is characterized by non-caseating epithelioid cell granulomas with giant cells mainly in the lung. Worldwide, the average incidence is 16 (male) and 19 (female) per 100,000 inhabitants. In some studies, it was described that patients with sarcoidosis have a higher risk of malignancies, especially of lung cancer. The results differ in the available studies. The role of smoking can probably be neglected as far as the development of lung cancer is concerned, because the patients with sarcoidosis are mainly non-smokers. Regarding all of the published clinical studies with totally 22,439 patients with sarcoidosis, a coexistence of sarcoidosis and lung cancer was detected only in 0.7% of the patients. According to the published case reports, mostly squamous lung cell carcinoma was histologically found, followed by adenocarcinoma. These results indicate that the coexistence of sarcoidosis and lung cancer is very rare. Pathol....
Sarcoidosis is a multisystemic disorder of unknown origin which is characterized by noncaseating ... more Sarcoidosis is a multisystemic disorder of unknown origin which is characterized by noncaseating epithelioid cell granulomas with giant cells mainly in the lung. The average incidence is worldwide 16 (male) and 19 (female) per 100,000 inhabitants. In some studies it was described that patients with sarcoidosis have a higher risk of malignancies, especially of lung cancer. The results differ in the available studies. The role of smoking can probably be neglected as far as the development of lung cancer is concerned, because the patients with sarcoidosis are mainly non smokers. Regarding all of the published clinical studies with totally 22,439 patients with sarcoidosis, a coexistence of sarcoidosis and lung cancer was detected only in 198 (0.9 %) patients. According to the published case reports, mostly squamous lung cell carcinoma was histologically found, followed by adenocarcinoma. These results indicate that the coexistence of sarcoidosis and lung cancer is very rare.
DMW - Deutsche Medizinische Wochenschrift, 2008
Journal of Thoracic Oncology, 2007
standard treatment for this age group. Several recent studies suggest superiority of combination ... more standard treatment for this age group. Several recent studies suggest superiority of combination CT, but little is known about QoL during CT. Also better assessments are needed to select elderly pts suitable for combination CT. The aim of this study was to investigate the effect of both platinum-based regimens on changes in QoL and the tolerability of these treatments in elderly NSCLC pts. Methods: Eligible were pts ≥ 70 years with advanced NSCLC. They received carboplatin (AUC 5 day 1)-gemcitabine (1250 mg/m 2 days 1 and 8) or carboplatin (AUC 5 day 1)-paclitaxel (175 mg/m 2 day 1), q 3 weeks, for a maximum of 4 cycles. Darbepoetin was started if Hb < 11 g/dL. Primary endpoint was the change in global QoL from baseline compared with week 18, using the EORTC QLQ-C30. Among the secondary endpoints were toxicity, response rate and survival. In addition, the value of a comprehensive geriatric assessment (CGA) was used. Results: 182 pts were randomized. At the time of this analysis information was available on 168 pts. Mean age was 75 yrs (range 70-85). PS = 0 in 30%, 1 in 57% and 2 in 13%. 64% of pts completed all 4 cycles, 10% stopped treatment prematurely due to toxicity, 13% due to PD. Toxicity related dose-reductions occurred in 28 and 8% of pts and dose-delays in 15 and 3% of pts in the CG and CP arm, respectively. Overall, grade III/IV toxicity occurred in 65% of pts (75% in CG arm, 56% in CP arm), toxicity related SAEs in 17% (20% in CG arm, 15% in CP arm), and 36% experienced ≥ grade 2 neurological toxicity (30% CG arm, 43% CP arm). Response rates were 28% in the CG arm vs 20% in the CP arm. Median survival and progression-free survival were 7.7 and 4.7 months for the CG arm and 6.6 and 4.4 months for the CP arm, respectively. 56 % of pts in the CG arm and 49% in the CP arm completed both the QoL questionnaires at baseline and after 18 weeks. Mean global QoL score at baseline did not differ between both arms (66% for GC and CP). After 18 weeks the mean QoL score for the CG arm had decreased by 2% and for the CP arm by 8% (NS). Furthermore, changes in Qol scores over the period of 18 weeks did not differ significantly between both treatment arms. For experiencing grade III/IV toxicity related SAEs, neurological toxicities and for finishing all cycles, the use of a CGA was of predictive value. Conclusions: In elderly patients with advanced NSCLC differences in treatment-related toxicity from gemcitabine and paclitaxel administered with carboplatin have no differential influence on QoL. Response and survival rates are similar for both groups.
Atemwegs- und Lungenkrankheiten, 2006
Atemwegs- und Lungenkrankheiten, 2005
Atemwegs- und Lungenkrankheiten, 2010
Atemwegs- und Lungenkrankheiten, 2010
Sarcoidosis is a multisystem inflammatory disease of unidentified aetiology, which manifests as n... more Sarcoidosis is a multisystem inflammatory disease of unidentified aetiology, which manifests as noncaseating granulomas. It is hypothesised that sarcoidosis has an antigenic or inflammatory trigger that initiates the immune reaction in a susceptible host. Research is focusing on the correlation between sarcoidosis and exposure to airborne antigens, such as tree pollen, insecticides, mouldy environments, and inorganic particles. There are indications, that microbial cell wall agents, particularly agents from fungi, even in the absence of clinical infections can cause a late hypersensitivity reaction leading to granulomas. The occurrence of bacterial or fungal infections in sarcoidosis was repeatedly described and DNA or proteins of microbial organisms have been found. Cladosporium species were significantly enriched in specimen of patients with sarcoidosis. It is presumed that different inhaled microbial exposures, including moisture damage, can increase the risk of sarcoidosis, a ca...
Deutsche medizinische Wochenschrift, 2002
Sarcoidosis is a multisystemic disorder of unknown origin, which is characterized by non-caseatin... more Sarcoidosis is a multisystemic disorder of unknown origin, which is characterized by non-caseating epithelioid cell granulomas with giant cells mainly in the lung. Worldwide, the average incidence is 16 (male) and 19 (female) per 100,000 inhabitants. In some studies, it was described that patients with sarcoidosis have a higher risk of malignancies, especially of lung cancer. The results differ in the available studies. The role of smoking can probably be neglected as far as the development of lung cancer is concerned, because the patients with sarcoidosis are mainly non-smokers. Regarding all of the published clinical studies with totally 22,439 patients with sarcoidosis, a coexistence of sarcoidosis and lung cancer was detected only in 0.7% of the patients. According to the published case reports, mostly squamous lung cell carcinoma was histologically found, followed by adenocarcinoma. These results indicate that the coexistence of sarcoidosis and lung cancer is very rare. Pathol....